The Lead Episode 38: A Discussion of Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation

Discussion Topic: Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation

Janice Y. Chyou, MD, FHRS, of Icahn School of Medicine at Mount Sinai is joined by guests Jonathan P. Piccini, Sr., MD, MHS, FHRS, of Duke University Medical Center, and Mintu P.Turakhia, MD, MS, of iRhythm Technologies and Stanford University to have A Discussion of Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation. Subclinical atrial fibrillation is short-lasting and asymptomatic and can usually be detected only by long-term continuous monitoring with pacemakers or defibrillators. Subclinical atrial fibrillation is associated with an increased risk of stroke by a factor of 2.5; however, treatment with oral anticoagulation is of uncertain benefit. Among patients with subclinical atrial fibrillation, apixaban resulted in a lower risk of stroke or systemic embolism than aspirin but a higher risk of major bleeding.

Host: Janice Y. Chyou, MD, FHRS
Guests: Jonathan P. Piccini, Sr., MD, MHS, FHRS and Mintu P. Turakhia, MD, MS

Speaker and Article Information: Download

• Listen on HRS365
• Listen on Apple Podcasts
• Listen on Spotify